Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. St. Jude seeks shareholder approval for Abbott merger
St. Jude Medical is reaching out to shareholders to approve its proposed $25 billion merger with Abbott, according to an SEC filing posted today.
The St. Paul, Minn.-based company said the deal will put $46.75 cash in the hands of each stock holder for every share they hold, as well as 0.87 shares of Abbott for each share of St. Jude. The company said no fractional shares will be issued, and that any fractional shares will be paid in cash. Read more
4. Elekta touts MR-imaging radiotherapy combo at ASTRO
Richard Hausmann built his career on the physics of imaging – he spent 23 years at Siemens and 4 years at GE developing the magnetic resonance and computerized tomography businesses before joining Elekta as president & CEO in June 2016.
Hausmann told MassDevice.com yesterday that Elekta’s new MR-linac system, which combines MR imaging and radiotherapy for localized tumor treatment, is a “paradigm shift” in treating cancer. Read more
3. Japanese regulators approve Abiomed’s Impella heart pumps
Abiomed said today that it won approval from the Japanese Ministry of Health, Labor & Welfare’s Pharmaceuticals & Medical Devices Agency for its Impella line of heart pumps.
The Danvers, Mass.-based company said its devices are the “1st and only percutaneous temporary ventricular support devices” to win Japanese PMDA approval and be deemed safe and effective for their indication. Read more
2. Gore wins Medicare add-on status for Excluder stent graft
W.L. Gore & Assoc. said today that it won new technology status from the U.S. Centers for Medicare & Medicaid Services for its Gore Excluder iliac branch endoprosthesis.
Set to go into effect Oct. 1, the change will allow facilities that use the device, in conjunction with Gore’s Excluder AAA device for endovascular aneurysm repair, to be eligible for a new tech add-on payment of up to $5,250 per case. The payment will come in addition to the applicable base payment for the Medicare Severity Diagnosis-related group. Read more
1. Boston Scientific to pay $210m for EndoChoice
Boston Scientific said today that it agreed to pay $210 million for EndoChoice and its line of devices for treating gastrointestinal disease.
The $8-per-share offer is slated to close by the end of the year, the companies said. EndoChoice took itself public in June 2015 with an IPO that brought in some $96 million. Read more
The post MassDevice.com +5 | The top 5 medtech stories for September 27, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/2dpwiR9
Cap comentari:
Publica un comentari a l'entrada